Skip to main content

Table 5 Productivity loss averted

From: Modeling the potential economic benefits of an oral SARS-CoV-2 vaccine during an outbreak of COVID-19

 

Deaths

Productivity Loss (Low)

Productivity Loss (Low)

Productivity Loss (High)

All Variants

Status Quo

137,829

$744,276,600,000

$1,585,033,500,000

$2,412,007,500,000

Oral Vaccine Scenario 1

107,455

$580,257,526,181

$1,235,733,620,571

$1,880,464,205,216

Averted Scenario 1

30,374

$164,019,073,819

$349,299,879,429

$531,543,294,784

Oral Vaccine Scenario 2

100,729

$543,934,686,154

$1,158,379,424,216

$1,762,751,297,721

Averted Scenario 2

37,100

$200,341,913,846

$426,654,075,784

$649,256,202,279

Omicron

Status Quo

112,322

$606,536,502,230

$1,291,698,106,600

$1,965,627,553,522

Oral Vaccine Scenario 1

86,612

$467,707,425,230

$996,043,590,768

$1,515,718,507,691

Averted Scenario 1

25,709

$138,829,076,999

$295,654,515,832

$449,909,045,831

Oral Vaccine Scenario 2

81,118

$438,038,940,274

$932,860,706,138

$1,419,570,639,775

Averted Scenario 2

31,203

$168,497,561,956

$358,837,400,462

$546,056,913,747